Navigation Links
Amylin Responds to Eastbourne Letter
Date:5/20/2009

d in this letter, may not be submitted timely or receive FDA approval; risks that our expense reductions will not be as large as we expect; risks that the restructured operations for exenatide will not produce the results we expect; and other risks inherent in the drug development and commercialization process. Commercial and government reimbursement and pricing decisions and the pace of market acceptance may also affect the potential for BYETTA, SYMLIN or exenatide once weekly. These and additional risks and uncertainties are described more fully in the Company's most recently filed Form 10-K and Form 10-Q. Amylin disclaims any obligation to update these forward-looking statements.

Additional Information and Where To Find It

This press release may be deemed to be solicitation material in respect of the matters to be considered at the 2009 Annual Meeting of Stockholders. Amylin has filed the definitive proxy statement with the Securities and Exchange Commission ("SEC") on April 20, 2009. INVESTORS AND SECURITYHOLDERS ARE URGED TO READ THE PROXY STATEMENT, THE BLUE PROXY CARD AND ANY OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC BECAUSE THEY CONTAIN IMPORTANT INFORMATION. Investors and securityholders may obtain the proxy statement and other relevant documents free of charge at the SEC's Web site, www.sec.gov or from Amylin Investor Relations at 9360 Towne Centre Drive, San Diego, California 92121.

Participants in Solicitation

Amylin and its directors and executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies in respect of the matters to be considered at the 2009 Annual Meeting of Stockholders. Information regarding the interests of Amylin's directors and executive officer
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
2. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
3. Amylin Pharmaceuticals Reports Third Quarter Financial Results
4. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
5. Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors
6. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
7. Amylin Pharmaceuticals to Present at Nasdaq 20th Investor Program
8. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amylin Pharmaceuticals to Webcast First Quarter Results
10. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
11. Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... NASA astronaut Scott Kelly , who is ... a year living and working on the International Space Station, ... 7 a.m. EDT Monday, March 9. Kelly will ... the final weeks of his training. The interviews will be ... highlighting his mission training and previous spaceflights. To ...
(Date:3/3/2015)... TORONTO , March 3, 2015 /CNW/- SQI Diagnostics ... and commercializes proprietary technologies and products for advanced ... Ryer CPA, CA, CFE  to its Management team. ... the Company in its transition from a development ... financing initiatives to advance the Company,s capital market ...
(Date:3/3/2015)... Fried, Frank, Harris, Shriver & Jacobson LLP ... joined the Firm as a partner in the Intellectual ... York office. Mr. Lewis concentrates on patent ... other intellectual property and general litigation. A trained chemical ... plaintiffs and defendants in a range of technology-related sectors ...
(Date:3/3/2015)... , March 3, 2015  Rosa & Co. ... drug-disease modeling and simulation research, today announced it has ... American Society for Clinical Pharmacology and Therapeutics meeting in ... 2015.   Logo - http://photos.prnewswire.com/prnh/20150302/179058LOGO   ... will present a poster describing a quantitative systems pharmacology ...
Breaking Biology Technology:NASA Astronaut Scott Kelly Available for Interviews before One-Year Space Station Mission 2SQI Diagnostics Appoints Chief Financial Officer 2SQI Diagnostics Appoints Chief Financial Officer 3Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 3Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 2Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 3
... for, Therapeutic Radiology and Oncology (ASTRO) meeting in Boston, September ... ... Booth # 547 -- Varian,Medical Systems (NYSE: VAR ), world leader ... full,spectrum of technologies and products for planning and delivering fast,precise cancer treatments ...
... of Oral Calcitonin, a,combination of Salmon Calcitonin and ... KNOLLS, N.J., Sept. 22 Emisphere,Technologies, Inc. (Nasdaq: ... AG,and Nordic Bioscience have completed recruitment for a ... of an oral formulation of,salmon calcitonin using Emisphere,s ...
... 22 Kiadis Pharma announced today,that its lead ... by the European Medicines Agency (EMEA) for the ... an allogeneic bone marrow,transplantation., "Following the orphan ... lead,product ATIR(TM), this is another important milestone in ...
Cached Biology Technology:Varian Medical Systems Exhibits a New Version of RapidArc(TM) Radiotherapy Technology and Other Products for Fast, Precise Cancer Treatment 2Varian Medical Systems Exhibits a New Version of RapidArc(TM) Radiotherapy Technology and Other Products for Fast, Precise Cancer Treatment 3Varian Medical Systems Exhibits a New Version of RapidArc(TM) Radiotherapy Technology and Other Products for Fast, Precise Cancer Treatment 4Emisphere Announces Recruitment Phase III Study for Oral Osteoarthritis Treatment 2Emisphere Announces Recruitment Phase III Study for Oral Osteoarthritis Treatment 3EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation 2
(Date:2/5/2015)... TRIANGLE PARK, N.C. , Feb. 5, 2015 /PRNewswire/ ... a specialist logistics company and has launched a new ... only Clinical Logistics Organization (CLO).  The new campaign focuses ... emphasis on patient, protocol and shipments. The ... First , aligns Marken,s priorities with its client,s ...
(Date:2/5/2015)... , Jan. 28, 2015 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... the upcoming RedChip Global Online CEO Conference on January ... Gino Pereira , CEO of NXT-ID will ... lead product, the Wocket smart wallet and its full ...
(Date:1/22/2015)... Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to inform ... State of Washington,s Department of Licensing, in the ... issuance system for driver,s licenses and identification cards to its ... development will start in January 2015, with enrollment and card ...
Breaking Biology News(10 mins):Marken Launches New Patient-Centric Campaign 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Valid USA Signs Contract For Washington Driver's License Issuance 2
... from the Virginia Bioinformatics Institute (VBI) at Virginia Tech ... a large family of virulence proteins that play an ... the plant pathogen Phytophthora sojae. VBI Professor ... with researchers from Virginia Techs Department of Plant Pathology, ...
... Gel-like material shows promise as oral insulin ... report development of a gel-like material that could help speed ... a pill by mouth, rather than with injections. The study ... a monthly journal. In the report, Nicholas A. Peppas ...
... Software Is Force Multiplier for Shelbyville Police ... BIO-key International,Inc. (OTC Bulletin Board: BKYI), a ... safety solutions, today announced the,award of a ... for the Department,s first mobile data system. ...
Cached Biology News:American Chemical Society's Weekly PressPac -- April 16, 2008 2American Chemical Society's Weekly PressPac -- April 16, 2008 3American Chemical Society's Weekly PressPac -- April 16, 2008 4American Chemical Society's Weekly PressPac -- April 16, 2008 5American Chemical Society's Weekly PressPac -- April 16, 2008 6American Chemical Society's Weekly PressPac -- April 16, 2008 7American Chemical Society's Weekly PressPac -- April 16, 2008 8BIO-key(R) Receives New Mobile Data Contract Award From Indiana Police Agency 2BIO-key(R) Receives New Mobile Data Contract Award From Indiana Police Agency 3
... Kit is an in vitro enzyme ... of human Gla-OC in serum, cultured ... other biological fluids. This kit ... is not for use in diagnostic ...
Human Aminopeptidase P2/XPNPEP2 Affinity Purified PAb ENTREZ GeneID: 7512...
... strains are K-12 derivatives that have mutations ... glutathione reductase (gor) genes, which greatly enhances ... have shown that expression in Origami(DE3) yielded ... host even though overall expression levels were ...
... All serum is extensively ... release criteria. All horses ... Diet and worming are controlled ... to lot consistency. Pricing: ...
Biology Products: